Sign In
Buy SAN
$12.47
+0.310 (+2.55%)
At Close: Jun 04, 2026
Des données de phase III de dernière heure relatives à Dupixent® (dupilumab) présentées à la Semaine UEG 2022 montrent une rémission histologique significative de l’œsophagite à éosinophi
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years old
05:00am, Tuesday, 11'th Oct 2022 GlobeNewswire Inc.
Dupixent® (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years old
Why Shares of Banco Santander Brasil, Banco Bradesco, and Itau Unibanco Holding Are Rising Today
02:36pm, Monday, 03'rd Oct 2022
Investors are reacting to the results of the first round of Brazil's presidential election.
Banco Santander: Trading At Less Than 0.6 Times TBV And 5 Times Earnings
11:30am, Thursday, 29'th Sep 2022
Banco Santander is a Spanish bank, but generates most of its income from abroad. The share price has been sliding as recession fears are hitting the world economy.
Press Release: Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis
10:05pm, Wednesday, 28'th Sep 2022 GlobeNewswire Inc.
Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis
Communiqué de presse: Dupixent® (dupilumab), premier et seul médicament approuvé par la FDA pour le traitement du prurigo nodulaire
10:05pm, Wednesday, 28'th Sep 2022 GlobeNewswire Inc.
Dupixent® (dupilumab), premier et seul médicament approuvé par la FDA pour le traitement du prurigo nodulaire
Communiqué de presse : Mise en ligne du document «Q3 2022 Memorandum for modelling purposes»
05:30am, Wednesday, 28'th Sep 2022 GlobeNewswire Inc.
Mise en ligne du document «Q3 2022 Memorandum for modelling purposes»
Press Release: Availability of the Q3 2022 Memorandum for modelling purposes
05:30am, Wednesday, 28'th Sep 2022 GlobeNewswire Inc.
Availability of the Q3 2022 Memorandum for modelling purposes
'Some companies are closing their doors, others are shutting down divisions': Rocket CEO outlines plans to navigate the dramatic decline in mortgages
01:52pm, Saturday, 24'th Sep 2022 MarketWatch
Rocket, which owns Rocket Mortgage, Rocket Money, and more, is planning to diversify its approach to reach more consumers, on top of offering discounts to lower monthly payments.
Press Release: CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infants
06:00am, Friday, 16'th Sep 2022 GlobeNewswire Inc.
CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infants
Communiqué de presse: Le CHMP recommande l’approbation de Beyfortus® (nirsevimab) pour la prévention des infections par le VRS chez le nourrisson
06:00am, Friday, 16'th Sep 2022 GlobeNewswire Inc.
Le CHMP recommande l’approbation de Beyfortus® (nirsevimab) pour la prévention des infections par le VRS chez le nourrisson
Sanofi: Informations relatives au nombre de droits de vote et d'actions - AOUT 2022
07:24pm, Tuesday, 13'th Sep 2022 GlobeNewswire Inc.
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement
Sanofi: Information concerning the total number of voting rights and shares - August 2022
07:24pm, Tuesday, 13'th Sep 2022 GlobeNewswire Inc.
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement
Is WisdomTree Europe Hedged Equity ETF (HEDJ) a Strong ETF Right Now?
10:20am, Monday, 12'th Sep 2022 Zacks Investment Research
Smart Beta ETF report for HEDJ
Communiqué de presse: Des données de phase III de dernière heure présentées au Congrès de l’EADV 2022 montrent que Dupixent® (dupilumab) améliore significativement les signes et symptômes du prurigo nodulaire
03:30pm, Thursday, 08'th Sep 2022 GlobeNewswire Inc.
Des données de phase III de dernière heure présentées au Congrès de l’EADV 2022 montrent que Dupixent® (dupilumab) améliore significativement les signes et symptômes du prurigo nodulaire
